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ABSTRACT

ARTICLE HISTORY

Context: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are a novel treatment approved
for type 2 diabetes mellitus to lower hyperglycemia, systolic blood pressure, and promote
weight loss. Commonly reported serious adverse events include increased mycotic urogenital
infections, orthostatic hypotension, and normoglycemic ketoacidosis.
Case report: We present a case of a 47-year old man with a history of type 2 diabetes mellitus
initiated on the SGLT-2 inhibitor canagliflozin preoperatively before a penile implant, who presented with late postoperative MRSA bacteremia and scrotal abscess requiring implant extraction.
Conclusion: As the SGLT-2 inhibitors are gaining in popularity, prescribers must be aware of
the potential adverse genitourinary infectious outcomes. Providers should use caution and
avoid initiating SGLT-2 inhibitors in the perioperative setting, and may even consider holding
or discontinuing this medication in the setting of impending GU surgery.
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1. Introduction
Sodium glucose co-transporter 2 (SGLT-2) inhibitors are
a relatively new class of oral hypoglycemic medications
used for type 2 diabetes mellitus via an insulinindependent mechanism [1]. On 29 March 2013, canagliflozin became the first FDA approved SGLT-2 inhibitor
for type 2 diabetes mellitus [2]. Since approval it has been
shown to lower hemoglobin A1c in those patients who
have not achieved adequate control with diet and exercise
[3]. In addition, SGLT-2 inhibitors have also been shown
to lower blood pressure and promote weight loss.
However, an increased risk of genital mycotic infections,
orthostatic hypotension, and normoglycemic ketoacidosis have been reported [4]. Unfortunately, the specific
incidence of urinary tract infections has not been well
established in the setting of genitourinary (GU) surgery.

2. Case presentation
A 47-year old man with a history of diabetes mellitus
Type 2 presented with acute onset progressive scrotal
swelling, pain and fever three weeks following penile
implant surgery. Medications on admission included
canagliflozin-metformin, added immediately preceding
surgery to improve his perioperative glucose control. On
physical examination, the patient was febrile with scrotal
swelling and tenderness to palpation. Laboratory evaluation was unremarkable including WBC count of 7500 c/
mm3 and serum lactate of 1.0 meq/L. Urinalysis was
positive for glucose and trace ketones but negative for
bacteria and white cells. A CT pelvis identified scrotal
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fluid consistent with abscess, and he was brought to the
OR for penile prosthesis explant. Cultures grew MRSA
and gram-negative rods. Blood cultures found MRSA
bacteremia on second day of hospitalization. The patient
was eventually discharged on IV vancomycin and amoxicillin-clavulanic acid for 14 days. In addition, the
patients SGLT-2 inhibitor, canagliflozin, was discontinued. The incident was reported to the FDA’s postmarketing surveillance system.

3. Discussion
SGLT-2 inhibitors are a novel treatment option for Type
2 diabetes mellitus which have been shown to lower
hyperglycemia, systolic blood pressure, and promote
weight loss [5] with reported adverse events including
infections involving the GU tract due to the medication
mechanism of action [6]. Approximately 180g of glucose
is filtered through the renal system daily with almost 90%
reabsorbed in the proximal tubule by the glucose transporter protein, SGLT-2 [7]. Canagliflozin is a selective
SGLT-2 inhibitor which increases urinary excretion of
glucose but is associated with an increased rate of GU
infections [8]. The incidence of GU infections on an
SGLT-2 inhibitor in the setting of GU surgery has not
been described, but caution should be taken in perioperative use of this class in light of this risk.
This case highlights the potential risks of hyperglucosuria in the face of genitourinary surgeries. Although a
single case report, there have been numerous other
reports of genitourinary infection rates in non-surgical
patients that make this association possibly causative.
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Providers should use caution and avoid initiating SGLT-2
inhibitors in the perioperative setting, and may even
consider holding or discontinuing this medication in
the setting of impending GU surgery. If perioperative
glucose control is needed in patients undergoing GU
surgery, other hypoglycemic agents should be considered.
Further studies are needed to determine if providers
should avoid SGLT-2 inhibitors in the perioperative period for GU surgeries, and if so, for how long.
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